Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Dancey

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2021
CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLCNatasha B Leighl, Scott A Laurie, Glenwood D Goss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerMaura N Dickler, Hope S Rugo, Carey A Eberle, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.
JCO Global Oncology|September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to ArmsKamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Breast Cancer Research and Treatment|December 18, 2012
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancerCynthia X Ma, Matthew J C Ellis, Gina R Petroni, et al.
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO groupNancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, et al.
Cancer Chemotherapy and Pharmacology|August 10, 2010
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesPaula M Fracasso, Kerry J Williams, Ronald C Chen, et al.
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2021
CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLCNatasha B Leighl, Scott A Laurie, Glenwood D Goss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerMaura N Dickler, Hope S Rugo, Carey A Eberle, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.
JCO Global Oncology|September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to ArmsKamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Breast Cancer Research and Treatment|December 18, 2012
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancerCynthia X Ma, Matthew J C Ellis, Gina R Petroni, et al.
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO groupNancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, et al.
Cancer Chemotherapy and Pharmacology|August 10, 2010
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesPaula M Fracasso, Kerry J Williams, Ronald C Chen, et al.
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
Pageof 8